Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.
EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment
EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma
EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma
EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma
EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma
EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma
EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
EP: 11.Complying with REMS Training and Documentation Requirements
EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
EP: 13.Unmet Needs in Multiple Myeloma Care
EP: 14.Treatment Sequencing and Combination Therapies for MM
EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM
This is a video synopsis/summary of a Practice Pearls involving Ryan Haumschild, PharmD, MS, MBA; Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.
The specialists discuss operational considerations for the U.S. Food and Drug Administration (FDA) required risk evaluation and mitigation strategies (REMS) programs associated with bispecific antibodies for relapsed/refractory multiple myeloma. At Perissinotti’s center, a pharmacy manager handles REMS program enrollment/documentation for the health system while physicians like Pianko must also complete their specific REMS requirements. Haumschild notes a best practice is having a pharmacist lead coordinate all providers’ REMS enrollment since coverage is needed if the primary prescriber is unavailable.
The REMS requires provider training on cytokine release syndrome/neurotoxicity risks and an enrollment form. Pharmacists must verify prescriber enrollment before every dispense and document it. Patients receive wallet cards about signs/symptoms requiring prompt attention. While rigorous, the REMS facilitates safe prescribing/dispensing of these novel immunotherapies, especially as community providers adopt them. Ongoing reattestation promotes continued competency.
Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.
